CJC-1295 + Ipamorelin
For: Growth hormone support
In plain language
This is the most common growth-hormone peptide pairing. CJC-1295 is a GHRH analog and ipamorelin is a selective ghrelin-receptor peptide, so the two raise growth hormone through different pathways at the same time. Human evidence for the combination itself is limited.
Components
Why these together
The pairing works on the idea of two complementary signals. CJC-1295 tells the pituitary to release growth hormone (the GHRH pathway), while ipamorelin amplifies that release through the ghrelin/GHS receptor. Ipamorelin is chosen over older peptides like GHRP-6 because it is selective and tends not to spike cortisol, prolactin, or hunger as much.
Evidence summary
The individual peptides have published pharmacology showing each can raise growth hormone. The specific combination is widely used in practice but has little controlled human trial data, so claims about its advantages over a single agent are not well established.
Each component has some human pharmacology data; the specific blend is not well trialed
Reported safety
Reported effects mirror the individual peptides: water retention, tingling, head rush after dosing, and possible effects on insulin sensitivity. Human safety of the combination is not formally established, and neither component is FDA-approved for these uses.
Frequently asked
Why combine a GHRH analog with a GHRP?
They act on two different receptors, so together they tend to produce a larger and more natural pulse of growth hormone than either one alone.
Is ipamorelin better than GHRP-6 here?
Ipamorelin is more selective, so it raises growth hormone with less of the hunger, cortisol, and prolactin response associated with GHRP-6.